PRLog - Jan. 15, 2013 - NEW YORK -- Belotero Balance® the newest FDA approved wrinkle eraser- a game changer
Belotero balance before and after nasolabial folds
The newest weapon on the war on wrinkles, Belotero Balance®, received FDA approval November, 2011. Merz Aesthetics, plans to officially launch it in early 2013. Limited supply of this product has been issued in the US thus far and the product has been receiving positive reviews. Its use has been in existence since 2006 in Europe.
Dr. Scott Blyer ( http://www.cameosurgery.com)
“While I typically use Radiesse® for adding volume to the cheeks and nasolabial folds, as the fold come to the superficial surface around the mouth, I have been unable to offer patients an effective predictable option until now. I would always tell my patients, fillers were not made to chase wrinkles, merely to add volume. This filler was made to chase wrinkles.”
It falls into the category of a hyaluronic acid filler like Juvederm®, Restylane®, or Perlane® but has properties which make it quite unique. The chemical nature of this product is a monophasic hyaluronic acid dermal filler with patented cohesive polydensified matrix technology. This technology is based on a dynamic double cross linking of the monophasic hyaluronic strands with the stabilizer BDDE (1-4 Butanediol Diglycidyl Ether). These properties allow for the filler to be injected smoothly, and very superficially while minimizing the risk of lumpiness.
Dr. Blyer further shares his experience with the tear trough area, under the eyes. “Restylane®
The syringes come in 1 cc and because the injections are performed so superficially, little is needed to note an effect. One syringe injected superficially can yield a more notable result than 2 syringes of a deeper filler.
While there are constantly European fillers moving into the US market, many are redundant in their limitations and usages. Belotero Balance® however, is a filler that can be used in areas doctors have regarded as taboo in the past. These are the superficial lines around the mouth, lips, and the eyes. Below the eyes, in the tear trough, a new door has opened which should allow patients another viable, predictable option for wrinkle reduction. The results are variable and last beyond 6 months. While this is not a wrinkle panacea it is approved only for the lower portion of the face, off label use has been promising.
Dr. Blyer is available for commentary via
646 201 5273
CAMEO Surgery Center
460 Park Ave (17th Floor)
New York, NY 11749